Strides Pharma Wins USFDA Closure for Key New York Formulations Plant

Strides Pharma Science Ltd ( (IN:STAR) ) has provided an announcement.

Strides Pharma Science Limited announced that its U.S. subsidiary, Strides Pharma Inc., has received an Establishment Inspection Report from the USFDA confirming closure of a recent inspection at its formulations facility in Chestnut Ridge, New York, which included a pre-approval review of drug-device combination capabilities for newly filed nasal spray products. The inspection, conducted in December 2025, was classified as Voluntary Action Indicated following the company’s response to observations, and the facility—responsible for liquids, gels, hormones, modified-release products and controlled substances for the U.S. market—is expected to benefit Strides’ near-term growth prospects and further solidify its U.S. business and regulatory standing as it continues to focus on high-quality, compliant pharmaceutical manufacturing for global markets.

More about Strides Pharma Science Ltd

Strides Pharma Science Limited is a Bengaluru-headquartered global pharmaceutical company focused on regulated markets, with a notable “in Africa for Africa” strategy and an institutional business serving donor-funded markets. The company manufactures difficult-to-make pharmaceutical products across facilities in India, Italy, Kenya and the United States, and sells its portfolio in more than 100 countries, with a strong presence in the U.S. through its New York formulations plant.

Average Trading Volume: 23,692

Technical Sentiment Signal: Buy

Current Market Cap: 77.02B INR

For an in-depth examination of STAR stock, go to TipRanks’ Overview page.